Journal of Clinical Pathology · 1999 · 302 citations · 9 references
MedicineMicrobiologyPharmacologyAntimicrobial PharmacologyMedical MicrobiologyMycologyAntifungal AgentsAntifungal PharmacologyAntifungal PharmacotherapyAntifungal TherapyAntimicrobial Susceptibility TestingAntifungal AntibioticsAntifungal TreatmentsCandida Albicans InfectionFungal Growth SuppressionNatural Antifungal CompoundsNew Antifungal AgentsYeast-mycelial Transition
AIM: To examine strains of Pseudomonas aeruginosa for specific antifungal factors. METHODS: Two clinical strains of P aeruginosa with strong in vitro inhibition (by cross streak assay) of Candida albicans and Aspergillus fumigatus were examined. Both strains were isolated from sputum--one from a patient with cystic fibrosis and one from a patient with bronchiectasis. Bacterial extracts were fractionated by high performance liquid chromatography and examined by ultraviolet absorbance and mass spectroscopy. Antifungal activity against C albicans and A fumigatus was determined in a well plate assay. RESULTS: Pyocyanin was the major antifungal agent of P aeruginosa; 1-hydroxy-phenazine also possessed activity. Pyocyanin MICs for C albicans and A fumigatus were > 64 micrograms/ml. These phenazines were active against nine other yeast species pathogenic for man. Preliminary experiments also suggested possible inhibition of yeast mycelial transformation in C albicans by pyocyanin. CONCLUSIONS: There may be a role for pyocyanin and 1-hydroxyphenazine in the prevention of pulmonary candidiasis in patients colonised by P aeruginosa.
9
Robert Wilson, David A. Sykes, David Watson et al. · Infection and Immunity · 1988 · 370 citations · Full text
Medicine, Microbiology, Pharmacology +17
Mechanisms of action of Pseudomonas aeruginosa pyocyanin on human ciliary beat in vitro
K Kanthakumar, Graham W. Taylor, K. Tsang et al. · Infection and Immunity · 1993 · 111 citations · Full text